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Botulinum toxin (BTX) treatment of upper limb is considered effective for upper limb spasticity 
following stroke and brain injury. Traditional method - Modified Ashworth Scale (MAS) is widely used 
for assessment of spasticity, however, it suffers from limitations including the lack of objective outcome 
measures and ignorance of the active movements. This pilot study is to develop a quantitative 
assessment utilizing inertial sensors tool for upper limb movement measurement and to investigate an 
objective measure of upper limb function for neurological patients before and after BTX treatment of 
spasticity. The system we proposed provides kinematic measurements of upper limb segment and joint 
motion data. In this study, four stroke patients were assessed by our proposed inertial sensing system 
immediately before and one week after BTX injection. In addition, patients were assessed using clinical 
assessment scales e.g. MAS, Disability Assessment Scale (DAS) and Motor Assessment Scale. The 
results showed that elbow Active Range of Motion (AROM) increased by 19 degrees on average and 
MAS and Motor Assessment Scale scores did not show significant change. The changes of the kinematic 
measures for patients 1-3 e.g. AROM, Rate of change of elbow joint angle, NJS, MUN and S-ratio all 
show that the inertial system is able to identify improvement in performance. This inertial sensing 
system provides additional and novel dynamic motion data for a sensitive and quantitative assessment of 
response to treatment and the efficacy of post-injection physiotherapy. 
 




Spasticity is a late complication after an injury to the Central Nervous System (CNS) e.g. multiple 
sclerosis, spinal cord injury and brain injury. It is characterized by a velocity-dependent increase in the 
muscle tone and resistance to passive stretch, which is caused by hyperactive stretch reflexes as first 
described by Lance in 1980 [1]. In addition, the presence of spasticity causes muscle stiffness and in 
some patients, muscle pain [2-4]. 
Therefore, untreated spasticity can limit the amount of exercise that a patient will tolerate and hence 
reduce the effectiveness of therapy and the rate of recovery. Current methods used to treat spasticity 
include oral anti-spasticity medications (e.g. baclofen) [5] and physiotherapy. More recently, Botulinum 
Toxin has proved an effective treatment for spasticity [6-8]. 
Traditionally the Ashworth Scale (AS) [9], MAS [10], DAS [11] and Goal Attainment Score (GAS) [12] 
are used to measure the spasticity of the upper limb and to assess response to treatment [13]. These 
spasticity scales measure resistance to passive movement of limb segments about a joint [14] or provide a 
measure of the patient's ability to perform selected tasks. However, the administration and scoring of 
spasticity using these assessment methods is thought to be very subjective. As a result, they are 
considered to have questionable validity and reliability [15-16] even though they are the standard 
spasticity and functional assessments. 
Measures such as MAS assess passive, rather than active movement, however active motion may have a 
closer relationship with function and be a better measure of patient response to treatment. Therefore, there 
has been a growing demand for a more objective and active assessment of upper limb spasticity and 
function. In response to this need methods for the objective assessment of spasticity and function have 
been developed. These include Isokinetic dynamometers [17-18], electro-goniometers [19], 
electromyography (EMG) [20] and the analysis of data from these techniques using biomechanical 
models [21]. Most isokinetic dynamometers can only measure passive motion and that motion in one 
plane only. EMG measurements also have limitations because of the administrative requirements and the 
impact of subject dependent factors on interpretation of the data, such electrode placement and muscle 
atrophy [22-24]. However, due to the lack of a Gold Standard to measure impairment level, major multi-
national clinical re-search still relies on AS or MAS to assess the efficacy of rehabilitation protocols, 
including anti-spastic agents like BTX [25, 26]. 
Therefore, a measurement system utilizing inertial sensors was developed to measure the kinematics 
(time dependent movement) of the upper limb segments in order to investigate whether upper limb 
spasticity, changes in spasticity and changes in function could be assessed in a more objective fashion. 
This system presents the time dependent 3D position and orientation of segment and joints throughout an 
assessment. The accuracy of position tracking utilizing this inertial measurement system has been shown 
to be within 0.1 cm over a movement distance of 10 cm and that of orientation to be within 1º [27]. The 
system was previously evaluated on five healthy volunteers and two patients with neurological disorders 
to obtain base line data [28]. 
This study on four neurological patients, follows on from the assessment and the system was used to 
investigate whether it is possible to monitor changes in spasticity and upper limb function immediately 
before and one week after Botox treatment. The data was analysed to provide the kinematic parameters of 
elbow extension AROM, rate of change of elbow joint angle, normalized jerk scores (NJS) [29], 
Movement Unit Number (MUN) [30] and upper limb joint/segment trajectory. This data and changes in 
the data are then compared with the traditional MAS and Motor Assessment scale measures. 
2. Methods 
2.1 Instrumentation 
In this study, a wearable system is used, which does not require a specialised set-up as required by the 
video systems of Vicon and Qualisys and can be used in any environment [28]. In this study Xsens MTx 
[31] inertial sensors are attached to the hand, forearm, upper arm and shoulder of each participant (Figure 
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1). Each inertial sensor comprises of a 3D accelerometer, gyroscope and magnetometer which enable 3D 
orientation tracking [27, 32]. Its dimension is 38*53*21 (W*L*H) (mm) and weight is 30 grams. A 
kinematic model was developed in order to translate the sensor movement from the sensor reference 
frames to that of the desired reference relative to the patient [27]. In this case the reference frame is 




Figure 1 Reference frames for the XSens MTx inertial sensor system. 
 
2.2 Participants 
Four participants undergoing BTX treatment were recruited (Table 1) to investigate the effect of that 
treatment on upper limb spasticity, including three men and one woman in the age range of 69-76y with a 
mean age of 73y. All participants were right handed, both upper limbs were affected and the left side 
most affected. Therefore, in this study the left upper limb was assessed. 
 
Table 1 Participant Information. 
Patient No. 1 2 3 4 
Gender Male Male Female Male 
Age 72 76 75 69 
Handedness Right Right Right Right 
Injected Side Left Left Left Left 
Stroke duration 2 yrs 4 yrs 4 yrs 2 yrs 
Brain Lesion 
Right MCA infarct 
(parietal lobe) 
Right thalamic infarct 
Right MCA infarction 
infarct 




(Dilution with 4ml 
normal saline) 
300 units 
(Dilution with 3ml 
normal saline) 
200 units 
(Dilution with 4ml 
normal saline) 
200 units 




Muscle Injected Bicep, FDP, FDS 
Pectoralis Major, FDP 
FDS, FCR, FCU 
FDP, FDS, Bicep FDP, FDS and Bicep 
and Brachioradialis  
Acronym: FDP: Flexor Digitorum Profundus, FDS; Flexor Digitorum Superficialis, FCU: Flexor Carpi Ulnaris, FCR: Flexor 
Carpi Radialis 
 
Written informed consent was obtained from each subject before enrolment and participation in this 
study. Ethics permissions were obtained from the UK NHS National Research Ethics Committee and the 
Hospital Institutional Review Board (IRB).  
2.3 Test Procedure 
Participants were seated on a chair or their own wheelchair in front of a fixed height test-table and four 
Xsens MTx inertial sensors were then aligned and attached with Velcro straps. 
Spasticity was assessed by use of the MAS, and up-per limb function by using DAS and Motor 
Assessment Scale. The inertial measurement system was used to monitor elbow active extension and to 
collect data during the nine-hole peg test, bean bag test and water drinking test. Because of the issue of 
patient fatigue, each test could only be implemented twice. All four subjects participated in two 
assessment sessions, one before and the second seven days after BTX treatment. 
Although the nine-hole peg test and bean-bag tests were carried out, this paper only presents the 
measurements and analysis for elbow extension and lower arm segment (wrist/hand) movement as these 
movements are assessed in the MAS. The analysis of the kinematic data includes presentation of joint 
angle against time, estimation of the elbow joint extension AROM [27, 32], hand trajectory in 3D space, 
and the MUN and NJS movement smoothness parameters [33]. The pre and post BTX treatment 
outcomes for the kinematic parameters and the MAS will be compared. 
3. Results 
In this paper, only the outcome of the elbow extension analysis and lower arm segment trajectory are 
presented. 
3.1 Active Range of Motion and Elbow extension time dependence 
The overall value of the AROM, its time dependence and the completion time are three important 
parameters which indicate the change of the subject' performance. In Figure 2, the time dependence of the 
elbow extension angle of a typical healthy participant and for two of the patients are presented. 
 
 
(a) Elbow extension of a normal participant 
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(b) Patient No.1 Pre- and post-BTX: Elbow extension 





































































(c) Patient No.2 Pre- and post-BTX Elbow extension 
Figure 2 Time dependence of Elbow extension angle 
 
A typical normal AROM of elbow flexion and ex-tension is 145-160° [34]. However, the elbow 
extension required for daily activities has been reported to be less than the normal anatomic range and can 
be as little as 30° [35]. In this case the normal had an AROM of 160° and an average angular velocity of 
215°/s. It can be seen from the plots that compared with normal function both participants had restricted 
AROMs and rate at which the movement is performed. For participant 1 there is improvement in 
movement with an increase in AROM from 17° to 39°, and a decrease in time from approximately 4 to 
2.5 seconds with an increase in rate of 4°/s to 15°/s. Similarly for participant 2, the AROM has increased 
from 38° to 63°. The time taken to perform the movement has decreased from approximately 3 to 1.5 
seconds, with an improvement in rate of change of angle from approximately 12°/s to 40°/s. Additionally 
the plot of joint angle against time provides information on the smoothness of the movement. In this case 
the movement for the normal is visually smother than that of the two patients. Because it is difficult to 
visually provide a numeric measure of these changes, additional parameters will be added to the 
automatic analysis - rate of change of joint angle and movement smoothness. 
3.2 Joint Position trajectory 
Figure 3 (a) shows the 2D upper limb segment position trajectory in the shoulder reference frame [27]. 
Figure 3 is that of the hand during the elbow extension test for a typical healthy subject while Figure 3 (c) 
and (d) show that of patient 1. A knowledge of the AROM and the segment lengths enables an estimate of 
the expected trajectory to be made. 
In Figure 3 (a), it can be seen that the normal volunteer with an elbow hand segment length of 
approximately 37 cm had a smooth movement, beginning with the hand about 22 cm in front of the 
shoulder (X displacement). The total displacement of the hand relative to the shoulder in the X axis is 
approximately 70 cm. The maximum displacement relative to the shoulder is approximately 28 cm in the 
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Y axis, rather than the expected 37 cm. This discrepancy can be accounted for by shoulder joint rotation 
during the AROM manoeuver. This type of movement is also likely to happen with the patients, who find 
the manoeuver very difficult and unconsciously compensate by rotating the shoulder joint. 
From Figure 3 (b) and Figure 3 (c) it can be seen that the patient, due to the effect of the spasticity, had 
very limited range of movement (17°). The restricted movement in the Y axis of a few mm and only 14 
cm in the X axis indicate that the majority of this manoeuvre was accomplished by compensatory rotation 
of the shoulder. Additionally, it can be seen that the movements show the presence of tremor. It can be 
seen that after the BTX injection (Figure 2 (b) and 3(d)), this uncontrolled movement has reduced and the 
range of the movement has increased (40°), with a 24 cm displacement in the X axis and 5cm in the Y 



















(a) Elbow extension and hand trajectory in the x-y plane of the shoulder reference frame 
































































(c) Patient No.1 Pre- BTX: Hand trajectory (d) Patient No.1 Post-BTX: Hand trajectory 
Figure 3 Hand Trajectory in the X-Y plane during elbow extension for a typical healthy subject and 
patient 1. 
 
The analysis of this data is time consuming and not straightforward. Therefore additional analysis 
techniques focusing on the kinematic parameters were investigated. 
3.3 Kinematic and Standard Assessment Parameters 
In addition to the orientation and trajectory related parameters introduced in the previous section, the 
following dynamic parameters have been selected to see whether they can indicate early changes in the 
effect of BTX on upper limb spasticity whilst performing the elbow AROM manoeuvre. 
 Active Range of Motion in extension - AROM (°). 
 Rate of change of elbow joint angle (°/s) whilst performing the AROM manoeuver. 
 Normalised Jerk Score (NJS) - a measure of the smoothness of movement [29] whilst performing 
the AROM manoeuver - the smaller the score the smoother the movement. 
 Movement Unit Number (MUN) - a measure of the smoothness of movement [30] whilst 
performing the AROM manoeuver - the smaller the MUN the smoother the movement. 
 Wrist Trajectory (m) - the measured distance travelled by the wrist (joint) in three dimensions 
during the AROM manoeuvre. 
 Ideal Wrist Trajectory for the measured AROM (m). This should be in two dimensions. 
 S-ratio (Actual wrist Trajectory /Ideal wrist Trajectory) - measure of closeness to the ideal for the 
given trajectory which normalises for changes in trajectory as the participant AROM improves. 
These measures are compared with the outcomes from the MAS and Motor Assessment scales in Table 2. 
 
Table 2 Clinical measurements and kinematic parameters. 
Elbow 
Extension 




Pre- 4 2 5 5 0 




Pre- 9 38 8 49 108 
Post- (% diff) 29(222%) 50(32%) 35(338%) 56(14%)  
AROM (deg) Pre- 17 38 36 49 160 
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Post- (% diff) 39 (129%) 63(65%) 51(42%) 63(29%)  
Rate of change 
of elbow joint 
angle (deg/s) 
Pre- 3.9 11.1 6.0 14.8 215 
Post- /(% diff) 14.8(279%) 39.2(255%) 14.2(137%) 16.4(11%)  
NJS 
Pre- 112 44 168 20 3 
Post-(% diff) 10(-91%) 3(-93%) 36(-79%) 46 (+130%)  
MUN 
Pre- 144 94 204 92 12 
Post-(% diff) 60(-58%) 50(-47%) 110(-46%) 116(+26%)  
Wrist 
Trajectory (m) 
Pre- 0.61 0.90 2.04 0.80 0.75 





Pre- 0.08 0.18 0.17 0.23 0.78 





Pre- 7.9 5 11.9 3.5 1.0 
Post-(% diff) 3.0(-62%) 2.8(-44%) 4.3(-64%) 5.1(+46%)  
 
4. Discussion 
4.1 Active Range of Motion and Elbow extension time dependence 
The graphical presentation of this data provides a visual representation in any of the axes, of joint rotation 
during the AROM. The AROM, time to perform the maneuver, approximate rate of change of angle, 
initiation, mid and final phases of joint rotation, as well as the smoothness of the movement can be 
deduced from this plot. Therefore an automated analysis system was developed to provide this 
information as well as additional kinematic parameters. Whether presenting the data in graphical format 
is of clinical value requires further investigation. 
4.2 Joint Position trajectory in the X-Y plane relative to the Shoulder reference Frame 
This is an example of one of the options for the presentation of segment movement. A comparison of 
normal and patient performance shows a significant difference in the way in which the extension of the 
elbow joint was achieved as well as being more sensitive than the MAS assessment to early improvement 
in the performance of the participants. However it is recognized that the greater the effect of spasticity on 
the patient, then the more abnormal the movement, or the greater the use of compensatory movements to 
perform the manoeuvre. 
4.3 Kinematic and Standard Parameters 
The MAS and Motor Assessment Scale show that the patients' performance was far from normal and all 
the patients have very limited active movement both before and a week after BTX treatment. In Table 2, 
it can be seen that any changes in MAS are not significant and those for the Motor Assessment scale, 
although improving are still significantly subnormal. It should also be noted that the Motor Assessment 
Scale tests includes activities which are not solely dependent on the use of the elbow joint and lower limb 
segment. Therefore lack of improvement in elbow joint function may be masked by improvements the 
mobility of the other joints. 
The kinematic analysis for elbow joint function for patients 1-3 shows an improvement in all the 
parameters, even though the values are still subnormal. The sensitivity of these parameters to change also 
seems to be better than that for the MAS. 
The NJS and MUN values for participants 1-3 show a reduction in jerkiness of movement indicating that 
although the BTX treatment has not yet had a significant effect on AROM, the muscle function relating to 
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smoothness of movement is significantly improved. The S-ratio, which is a measure of how much 
compensatory movement the participants are employing to complete the maneuver, indicates that 
although the AROM and joint angular velocities are still small, the movement of the lower arm segment 
around the elbow is approaching that of the normal 2D movement. How-ever it can be seen that patient 4 
response does not follow the general pattern. Although there are small improvements in MAS (5 to 4), 
Motor Assessment Scale (49 to 56) and AROM (49° to 63°) outcomes the kinematic measures there is a 
deterioration in NJS (20 to 46), MUN (92 to 116) and in the ideal limb segment trajectory S ratio (3.5 to 
5.1). This indicates that al-though the AROM has improved, control of the movement has not, or that 
compensatory movements have increased. This patient was also taking Baclofen which in terms of all the 
measurements presented in Table 2, seems to have reduced the expected effect of Botox. 
5. Conclusions 
The findings of present study indicate that the inertial measurement system may be able to provide early 
indication of changes in upper limb mobility and novel information about temporal and spatial 
characteristics of that movement which may not be evident in the more traditional measures. The 
measurement of active, rather than passive motion is also thought to be of particular value. This 
preliminary analysis indicates that this inertial measurement system could be used to detect early changes 
in upper limb response to Botox treatment for spasticity as well as add value for longer term analysis. 
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